Unlike some medicines that only treat bipolar I, CAPLYTA treats both bipolar I and II1-5

For bipolar I and II depression in adults

The first and only treatment for depressive episodes associated with bipolar I and bipolar II disorder in adults as monotherapy and adjunctive therapy (with lithium or valproate)1-5

Clinical studies evaluating adults with a depressive episode associated with bipolar disorder (bipolar depression)1-5

This table depicts antidepressant efficacy in adults with bipolar I or II depression as monotherapy and adjunctive therapy (with lithium or valproate).This table depicts antidepressant efficacy in adults with bipolar I or II depression as monotherapy and adjunctive therapy (with lithium or valproate).

BP=bipolar.

*With lithium or valproate.

There are no head-to-head clinical studies comparing the safety and efficacy of these products. This chart is descriptive of the FDA-approved indications in adults with bipolar depression and does not represent all approved indications for each product.

Proven antidepressant efficacy at 6 weeks as monotherapy and adjunctive therapy1,6,7*†

Change from baseline in MADRS total score1,6,7

This graph depicts the change from baseline in MADRS total score over 6 weeks for patients receiving CAPLYTA 42 mg or placebo as monotherapy or adjunctive therapy with lithium or valproate.This graph depicts the change from baseline in MADRS total score over 6 weeks for patients receiving CAPLYTA 42 mg or placebo as monotherapy or adjunctive therapy with lithium or valproate.

LSM=least squares mean; MADRS=Montgomery-Åsberg Depression Rating Scale.

†Monotherapy study placebo-subtracted difference was -4.6 (95% CI, -6.3, -2.8). Mean baseline MADRS total scores for CAPLYTA 42 mg and placebo were 30.8 and 30.3, respectively. Adjunctive therapy study placebo-subtracted difference was -2.4 (95% CI, -4.4, -0.4). Mean baseline MADRS total scores for CAPLYTA 42 mg and placebo were 32.2 and 32.1, respectively.1

‡The MADRS total score ranges from 0 to 60. Higher scores reflect greater symptom severity.

CAPLYTA separated from placebo as early as 1 week, continuing to 6 weeks1,6

Change in MADRS total score in monotherapy study1,6

This graph depicts the change from baseline in MADRS total score by week over a 6-week period for patients receiving CAPLYTA 42 mg or placebo as monotherapy.This graph depicts the change from baseline in MADRS total score by week over a 6-week period for patients receiving CAPLYTA 42 mg or placebo as monotherapy.

CAPLYTA—the maintenance dose is the starting dose

§P=nominal. The weekly time points prior to 6 weeks were not powered for statistical comparison and are descriptive only.

‖The primary endpoint was the change from baseline to 6 weeks in score on the Montgomery-Åsberg Depression Rating Scale (MADRS).2 Baseline MADRS Total Score: CAPLYTA 42 mg: 30.8; placebo 30.3.1

Improvement observed in individual MADRS item scores in bipolar I and II depression at 6 weeks9

Improvement in average baseline score in the monotherapy study9

This graph depicts the improvement based on least squares mean change from baseline to 6 weeks on individual MADRS items.This graph depicts the improvement based on least squares mean change from baseline to 6 weeks on individual MADRS items.

Limitation: These are exploratory endpoints; results require cautious interpretation.

Improvement based on least squares mean change from baseline on individual MADRS items scored 0-6.

Patients who were at risk for suicide were excluded from the clinical trials.

See the efficacy of CAPLYTA in disease severity
Disease Severity

CAPLYTA is indicated in adults for the treatment of schizophrenia and depressive episodes associated with bipolar I or II disorder (bipolar depression), as monotherapy and as adjunctive therapy with lithium or valproate.

Important Safety Information

Boxed Warnings:

  • Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. CAPLYTA is not approved for the treatment of patients with dementia-related psychosis.
  • Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adults in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors. The safety and effectiveness of CAPLYTA have not been established in pediatric patients.

Contraindications: CAPLYTA is contraindicated in patients with known hypersensitivity to lumateperone or any components of CAPLYTA. Reactions have included pruritus, rash (e.g., allergic dermatitis, papular rash, and generalized rash), and urticaria.

Warnings & Precautions: Antipsychotic drugs have been reported to cause:

  • Cerebrovascular Adverse Reactions in Elderly Patients with Dementia-Related Psychosis, including stroke and transient ischemic attack. See Boxed Warning above.
  • Neuroleptic Malignant Syndrome, which is a potentially fatal reaction. Signs and symptoms include hyperpyrexia, muscle rigidity, delirium, autonomic instability, elevated creatinine phosphokinase, myoglobinuria (and/or rhabdomyolysis), and acute renal failure. Manage with immediate discontinuation of CAPLYTA and provide intensive symptomatic treatment and monitoring.
  • Tardive Dyskinesia (TD), a syndrome of potentially irreversible, dyskinetic, and involuntary movements which may increase as the duration of treatment and total cumulative dose increases. The syndrome can develop after a relatively brief treatment period, even at low doses, or after treatment discontinuation. Given these considerations, CAPLYTA should be prescribed in a manner most likely to reduce the risk of TD. Discontinue CAPLYTA if clinically appropriate.
  • Metabolic Changes, including hyperglycemia, diabetes mellitus, dyslipidemia, and weight gain. Hyperglycemia, in some cases extreme and associated with ketoacidosis, hyperosmolar coma or death, has been reported in patients treated with antipsychotics. Measure weight and assess fasting plasma glucose and lipids when initiating CAPLYTA and monitor periodically during long-term treatment.
  • Leukopenia, Neutropenia, and Agranulocytosis (including fatal cases). Perform complete blood counts in patients with pre-existing low white blood cell count (WBC) or history of leukopenia or neutropenia. Discontinue CAPLYTA if clinically significant decline in WBC occurs in absence of other causative factors.
  • Orthostatic Hypotension and Syncope. Monitor heart rate and blood pressure and warn patients with known cardiovascular or cerebrovascular disease. Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension.
  • Falls. CAPLYTA may cause somnolence, postural hypotension, and motor and/or sensory instability, which may lead to falls and, consequently, fractures and other injuries. Assess patients for risk when using CAPLYTA.
  • Seizures. Use CAPLYTA cautiously in patients with a history of seizures or with conditions that lower seizure threshold.
  • Potential for Cognitive and Motor Impairment. Advise patients to use caution when operating machinery or motor vehicles until they know how CAPLYTA affects them.
  • Body Temperature Dysregulation. Use CAPLYTA with caution in patients who may experience conditions that may increase core body temperature such as strenuous exercise, extreme heat, dehydration, or concomitant anticholinergics.
  • Dysphagia. Use CAPLYTA with caution in patients at risk for aspiration.

Drug Interactions: Avoid concomitant use with CYP3A4 inducers. Reduce dose for concomitant use with strong CYP3A4 inhibitors (10.5 mg) or moderate CYP3A4 inhibitors (21 mg).

Special Populations: Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. Reduce dose for patients with moderate or severe hepatic impairment (21 mg).

Adverse Reactions: The most common adverse reactions in clinical trials with CAPLYTA vs placebo were:

  • Schizophrenia: somnolence/sedation (24% vs 10%) and dry mouth (6% vs 2%).
  • Bipolar Depression (Monotherapy, Adjunctive therapy): somnolence/sedation (13% vs 3%, 13% vs 3%), dizziness (8% vs 4%, 11% vs 2%), nausea (8% vs 3%, 9% vs 4%), and dry mouth (5% vs 1%, 5% vs 1%).

CAPLYTA is available in 10.5 mg, 21 mg, and 42 mg capsules.

Indications

CAPLYTA is indicated in adults for the treatment of schizophrenia and depressive episodes associated with bipolar I or II disorder (bipolar depression), as monotherapy and as adjunctive therapy with lithium or valproate.

Please see full Prescribing Information, including Boxed Warnings.

References: 1. CAPLYTA prescribing information. 2. Vraylar prescribing information. 3. Seroquel prescribing information. 4. Zyprexa prescribing information. 5. Latuda prescribing information. 6. Calabrese JR, Durgam S, Satlin A, et al. Efficacy and safety of lumateperone for major depressive episodes associated with bipolar I or bipolar II disorder: a phase 3 randomized placebo-controlled trial. Am J Psychiatry. Published online September 23, 2021. Accessed May 1, 2024. doi:10.1176/appi.apj.2021.20091339. 7. Suppes T, Durgam S, Kozauer SG, et al. Adjunctive lumateperone (ITI-007) in the treatment of bipolar depression: Results from a randomized placebo-controlled clinical trial [published online ahead of print, 2023 Feb 13]. Bipolar Disord. 2023;10.1111/bdi.13310. Accessed May 1, 2024. doi:10.1111/bdi.13310. 8. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389. Accessed May 1, 2024. 9. McIntyre RS, Durgam S, Kozauer SG, et al. The efficacy of lumateperone on symptoms of depression in bipolar I and bipolar II disorder: Secondary and post hoc analyses [published online ahead of print, 2023 Jan 12]. Eur Neuropsychopharmacol. 2023;68:78-88. Accessed May 1, 2024. doi:10.1016/j.euroneuro.2022.12.012.

Boxed Warnings:

  • Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. CAPLYTA is not approved for the treatment of patients with dementia-related psychosis.